What Is Semax? A Research Overview

Semax is a synthetic heptapeptide nootropic and neuroprotective agent developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, derived from the adrenocorticotropic hormone (ACTH) fragment containing amino acids 4 through 7 (Met-Glu-His-Phe), extended with a Pro-Gly-Pro stabilizing sequence. This structural design preserves the neurotrophic activity of the ACTH fragment while eliminating its hormonal (steroidogenic) effects and protecting the molecule from rapid enzymatic degradation. Semax has been approved in Russia and Ukraine for treating cognitive disorders, stroke recovery, and optic nerve conditions, and it is one of the most extensively studied nootropic peptides in Russian pharmacological research.

ACTH, the parent hormone from which Semax is derived, is a 39-amino-acid pituitary hormone that stimulates cortisol production from the adrenal cortex. However, the fragment ACTH(4-7) — which forms Semax's active core — was identified decades ago as possessing independent neurotrophic and cognitive-enhancing properties without triggering adrenal stimulation. Semax thus represents a successful example of isolating a neurotropic peptide sequence from a hormone with undesirable endocrine effects.

How Does Semax Work?

Semax's mechanism of action is centered on the regulation of neurotrophic factors, particularly brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF). Research has shown that Semax administration increases the expression of BDNF and its receptor TrkB in the hippocampus, prefrontal cortex, and basal forebrain — regions critical for memory, learning, and executive function. This neurotrophic upregulation promotes neuronal survival, dendritic branching, synaptogenesis, and long-term potentiation (LTP), the cellular mechanism underlying learning and memory.

Beyond neurotrophic effects, Semax modulates monoamine neurotransmitter systems. Studies have demonstrated increased dopamine and serotonin turnover in the brain following Semax administration, which may contribute to its effects on attention, motivation, and mood. Research also indicates that Semax can influence the expression of genes related to the immune response in the brain, including cytokines and chemokines, suggesting a role in neuroinflammatory modulation.

In ischemic stroke models, Semax has shown neuroprotective effects attributed to the stabilization of mitochondrial function, reduction of oxidative stress, inhibition of apoptotic signaling cascades, and promotion of angiogenesis in peri-infarct regions. These mechanisms collectively reduce infarct volume and improve functional recovery in preclinical models.

Key Research Findings

Study Focus	Model	Key Finding	Year
BDNF/NGF expression	Rat (brain)	Significant upregulation of BDNF and NGF mRNA in hippocampus and cortex	2005
Acute ischemic stroke	Human (clinical)	Improved neurological outcomes and reduced disability scores when used adjunctively	2007
Cognitive performance	Human (healthy volunteers)	Enhanced attention, memory, and information processing speed	2009
Optic nerve atrophy	Human (clinical)	Stabilization and modest improvement of visual function with intranasal administration	2011
Gene expression in ischemia	Rat (brain)	Modulation of 1,200+ genes in the first 24 hours post-ischemia, shifting expression toward neuroprotective patterns	2014

Common Research Applications

• Stroke recovery: Semax is used clinically in Russia as an adjunctive treatment for acute ischemic stroke, with research demonstrating improved neurological outcomes and reduced infarct progression.
• Cognitive enhancement: Studies explore Semax's effects on attention, working memory, and information processing in both healthy individuals and those with cognitive impairment.
• Optic nerve and retinal diseases: Russian clinical studies have investigated Semax for glaucomatous optic neuropathy and optic nerve atrophy, showing stabilization of visual function.
• ADHD research: Preliminary studies have examined Semax as a potential intervention for attention-deficit disorders, based on its dopaminergic modulation and attention-enhancing effects.
• Neurodegenerative disease: Early research investigates Semax's neuroprotective properties in models of Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions.

How Does Semax Compare?

Semax is most naturally compared to Selank, another Russian-developed heptapeptide with nootropic properties. While both enhance cognitive function, their primary mechanisms differ: Semax works primarily through BDNF/NGF upregulation and dopaminergic modulation (emphasizing cognitive performance and neuroprotection), while Selank targets GABA and serotonin systems (emphasizing anxiolysis and mood regulation). For a detailed side-by-side analysis, see our Selank vs. Semax nootropic comparison. Researchers often consider these peptides as complementary, with Semax targeting cognitive output and Selank addressing the emotional and stress-regulation components of brain function.

Safety and Considerations

Semax has been used clinically in Russia for over two decades, and the published literature reports a favorable safety profile. Common side effects are minimal, with occasional reports of mild nasal irritation when administered intranasally. No significant systemic adverse effects, hormonal disruption, dependence, or withdrawal symptoms have been documented in clinical studies. Importantly, despite being derived from ACTH, Semax does not stimulate the adrenal cortex or affect cortisol levels at standard research and clinical doses. However, most clinical evidence comes from Russian research institutions, and large-scale Western-standard trials are limited. Semax is not approved by the FDA or EMA. This information is for educational and research purposes only and does not constitute medical advice.

Frequently Asked Questions

Does Semax affect cortisol levels?

No. Despite being derived from the ACTH hormone, Semax is based on the ACTH(4-7) fragment, which does not possess steroidogenic (cortisol-stimulating) activity. The adrenal-stimulating portion of ACTH resides in a different region of the molecule (primarily the first 24 amino acids). Multiple studies have confirmed that Semax does not elevate cortisol or affect the hypothalamic-pituitary-adrenal axis.

How is Semax different from other nootropics like racetams?

Semax is a peptide-based nootropic that works primarily through neurotrophic factor upregulation (BDNF, NGF) and monoamine modulation, while racetams are small synthetic molecules that primarily modulate glutamatergic (AMPA receptor) signaling and acetylcholine activity. Semax's mechanism is more focused on promoting neuronal health and plasticity at a structural level, while racetams tend to enhance moment-to-moment neurotransmission efficiency.

Can Semax be taken long-term?

Published research on long-term Semax use is limited. Clinical protocols in Russia typically use Semax in defined courses (e.g., 10-14 days) with intervals between courses, rather than continuous indefinite use. Whether extended continuous administration offers additional benefits or carries different safety considerations remains an area requiring further research.